Literature DB >> 3390677

Sphincter of Oddi dysfunction: results of treatment by endoscopic sphincterotomy.

J P Neoptolemos1, I S Bailey, D L Carr-Locke.   

Abstract

From a consecutive series of 451 patients with post-cholecystectomy symptoms referred for endoscopic retrograde cholangiopancreatography (ERCP), 40 (9 per cent) were diagnosed as having sphincter of Oddi dysfunction. Eight patients were excluded from the study because of incomplete data (n = 6) or additional diagnoses (n = 2). Thirty of the patients had successful ERCP and endoscopic sphincterotomy (ES); this failed in the remaining two because of severe papillary stenosis (6.3 per cent). Endoscopic biliary manometry was performed in 23 patients (77 per cent). Immediate post-ES complications occurred in eight patients (25 per cent). At a median follow-up of 46 months (range 10-88 months) 19 patients had a good outcome (63.3 per cent) and 11 patients had a poor outcome (36.7 per cent). Patients with a good outcome tended to have a delay of months or years following cholecystectomy before the development of symptoms (median 6 years versus 0 years, P = 0.0003). At ERCP, patients with a good outcome had greater common bile duct diameters (mean +/- s.d. mm, 12.6 +/- 3.6 versus 8.8 +/- 1.8, P = 0.0003) and delayed drainage from the biliary tree of injected contrast (13 versus 2 patients, P = 0.02). Endoscopic biliary manometry was abnormal in all 15 patients with a good outcome in whom it was performed but in only 3 out of 8 patients with a poor outcome (P = 0.003). Sphincter of Oddi dysfunction is an important, albeit uncommon, cause of post-cholecystectomy symptoms. ES provides symptomatic relief in the majority of patients but improved criteria for predicting outcome are required.

Entities:  

Mesh:

Year:  1988        PMID: 3390677     DOI: 10.1002/bjs.1800750518

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  29 in total

Review 1.  Sphincter of Oddi dysfunction: the tales of two countries.

Authors:  W J Hogan
Journal:  Curr Gastroenterol Rep       Date:  2000-04

2.  Normokinetic biliary dyskinesia: a novel diagnosis.

Authors:  Christopher DuCoin; Robert Faber; Marlon Ilagan; William Ruderman; Daryl Wier
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

Review 3.  Complications of diagnostic and therapeutic ERCP.

Authors:  S A Cohen; J H Siegel; F E Kasmin
Journal:  Abdom Imaging       Date:  1996 Sep-Oct

4.  Feasibility of liver graft procurement with donor gallbladder preservation in living donor liver transplantation.

Authors:  Jia-Hong Dong; Sheng Ye; Wei-Dong Duan; Wen-Bing Ji; Yu-Rong Liang
Journal:  Hepatol Int       Date:  2015-05-15       Impact factor: 6.047

Review 5.  Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain.

Authors:  Lana Bistritz; Vincent G Bain
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

6.  Clinical and scintigraphic assessment of the role of endoscopic sphincterotomy in the treatment of sphincter of Oddi dysfunction.

Authors:  G M Fullarton; T Hilditch; A Campbell; W R Murray
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

Review 7.  Sphincter of Oddi dysfunction.

Authors:  G A Lehman; S Sherman
Journal:  Int J Pancreatol       Date:  1996-08

8.  Ampulla of Vater/duodenal wall spasm diagnosed by antroduodenal manometry.

Authors:  T Koussayer; T E Ducker; M H Clench; J R Mathias
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  Hepatoduodenal bile transit in cholecystectomized subjects. Relationship with sphincter of Oddi function and diagnostic value.

Authors:  E Corazziari; M Cicala; F I Habib; F Scopinaro; F Fiocca; N Pallotta; A Viscardi; A Vignoni; A Torsoli
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

10.  Intestinal dysmotility in patients with sphincter of Oddi dysfunction. A reason for failed response to sphincterotomy.

Authors:  E E Soffer; F C Johlin
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.